Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS

CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL

A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma

A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia

Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML